“As a precaution, Wockhardt UK Ltd is asking all health care professionals treating neonates and infants not to use Wockhardt’s Amoxicillin Sodium Powder for solution for injection (all batches) in such patients until further notice,” MHRA said in a drug alert issued earlier this week.
When contacted, a Wockhardt spokesperson declined to comment.
A Class Four alert is least critical in nature and is issued mainly as a precaution.
The regulator has also clarified that currently there is no evidence to suggest that Wockhardt’s product is defective.
MHRA is also working with the company to ensure the reports suggesting deviations are investigated at the earliest, the regulator said.
Last month, Wockhardt had recalled 8,000 bottles of anti-hypertension drug Metoprolol Succinate extended-release tablets in the US market following the failure of a dissolution test.
Analysts said the impact of the latest alert in the UK may not be huge on the financials of the company since the classification of the alert is only precautionary in nature and only the batches of the product used for children have been impacted. The alert includes three dosage sizes of Amoxicillin Sodium: 250mg, 500mg and 1gm.
However, given that Wockhardt is facing regulatory hiccups in the US and the UK markets, similar problems for a long time have the potential to increase stress on its revenues, analysts said. Some of the key facilities of the company in India are barred by the US Food and Drug Administration from supplying medicines to the American market, whereas some are also under the scanner of MHRA as it had identified some poor manufacturing practices at some sites.
On Friday, Wockhardt shares ended the session at Rs 570.55 on the Bombay Stock Exchange, up 0.33 per cent from their previous close. During the day, the stock touched a low of Rs 567.50.